publication date: May. 2, 2016

Melanoma Opdivo-Yervoy Combination Demonstrates Two-Year Survival Rate of 69 Percent   

Overall survival data from CheckMate-069, a phase II trial of a Opdivo and Yervoy combination regimen in patients with previously untreated advanced melanoma, demonstrated a two-year overall survival rate of 69 percent compared to 53 percent for Yervoy alone (HR=0.58 [95% CI: 0.31-1.08]) in patients with BRAF wild-type advanced melanoma.

CheckMate-069 evaluated 142 patients with previously untreated unresectable or metastatic melanoma who received either the Opdivo and Yervoy combination regimen (n=95) or Yervoy alone (n=47). The trial included patients with BRAF wild-type and BRAF V600 mutation-positive melanoma, and randomization was stratified by BRAF mutation status.

The primary endpoint was objective response rate in patients with BRAF wild-type tumors. Secondary endpoints included progression-free survival in patients with BRAF wild-type tumors, ORR in patients with BRAF V600 mutation positive tumors, and safety. Overall survival was an exploratory endpoint.

In the overall study population, the overall survival rate at two years was 64 percent for the Opdivo and Yervoy combination regimen, compared to 54 percent for Yervoy alone (HR=0.74 [95% CI: 0.43-1.26]). The safety profile of the Opdivo and Yervoy combination regimen in this study … Continue reading CCL April – Opdivo-Yervoy Combination Demonstrates Two-Year Survival Rate of 69 Percent

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2017 The Cancer Letter Inc.